drugset

drugset / Trial / NCT00583609

A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children

NCT00583609 ↗

Phase 4 Completed 20 enrolled Braintree Laboratories

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the patient acceptance of a new PEG3350 dose formulation in children currently treated with PEG3350 powder for treatment of constipation.

Timeline

Start: 2007-09
Primary completion: 2008-07
Completion: 2008-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	polyethylene glycol	Other / unclassified	—	—

Indications